NCT06969547 Mechanical Dyssynchrony and Microvascular Dysfunction by SPECT
| NCT ID | NCT06969547 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Condition | Myocardial Blood Flow Reserve |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2025-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2023-10-01 with a primary completion date of 2025-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The project is aimed at studying the feasibility of mechanical dyssynchrony of the left ventricle of the heart, determined by SPECT (gated MPI), as well as its stress-induced dynamics, in the evaluation of patients with coronary microvascular dysfunction in chronic coronary heart diseasу.
Eligibility Criteria
Inclusion Criteria: * Ischemia with no obstructive coronary arteries (INOCA) * Obstructive coronary artery disease (CAD) * Patients without evidence of coronary heart disease Exclusion Criteria: * Left ventricular ejection fraction \<55% according to echocardiography; * History of myocardial infarction/revascularization; * hypertension: systolic blood pressure \>180 mm Hg. Art., diastolic BP\>110 mm Hg. Art.; * systolic arterial hypotension \<80 mm Hg. Art.; * atrial fibrillation; * AV blockade of the III degree; sick sinus syndrome; * massive pulmonary embolism (PE) with a high degree of pulmonary hypertension; * the presence of significant valvular pathology (mitral insufficiency ≥ 3 degrees, aortic insufficiency ≥ 3 degrees, tricuspid regurgitation ≥ 3 degrees). * severe course of bronchial asthma, chronic obstructive pulmonary disease; * decompensated type 2 diabetes, * severe liver or kidney failure (glomerular filtration rate \<50 ml/min/1.73 m3 (CKD-EPI), * morbid obesity (body mass index \>45); * history of myocarditis * indications of poor drug tolerance; * oncological diseases; * chronic alcoholism, mental disorders; * other severe comorbidity, * refusal to participate in the study.
Contact & Investigator
Vladimir V Shipulin, MD, PhD
PRINCIPAL INVESTIGATOR
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Frequently Asked Questions
Who can join the NCT06969547 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Myocardial Blood Flow Reserve. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06969547 currently recruiting?
Yes, NCT06969547 is actively recruiting participants. Contact the research team at shipartphoto@gmail.com for enrollment information.
Where is the NCT06969547 trial being conducted?
This trial is being conducted at Tomsk, Russia.
Who is sponsoring the NCT06969547 clinical trial?
NCT06969547 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. The principal investigator is Vladimir V Shipulin, MD, PhD at Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences. The trial plans to enroll 75 participants.